HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR’s 161st Expert Panel Meeting: Much Ado About Airbrush Cosmetics; Prostaglandins Make 2023 Priorities

Executive Summary

Exactly what is in airbrush-delivered cosmetics, and how they are used by consumers, are not well understood by Cosmetic Ingredient Review, its expert panel, or the US FDA. At their June meeting, CIR’s independent experts debated who should be responsible for assessing airbrush cosmetics and how safety unknowns should be communicated.

You may also be interested in...



Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024

Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.

CIR Expert Panel’s Prostaglandin Review: Uncertainties Persist Around ‘Eye Makeup’ Ingredients

Cosmetic Ingredient Review’s expert panel issued an insufficient data announcement for two prostaglandin analogs at its June meeting in Washington. The group is reviewing the substances – related to the active ingredient in Allergan’s prescription drug Latisse for eyelash growth – after the US FDA indicated that they could be used lawfully in cosmetic products.

US Modernized Cosmetics Law’s ‘Weak’ Safety Substantiation Standard Leaves NGOs Wanting

Breast Cancer Prevention Partners and its Campaign for Safe Cosmetics, along with the Environmental Working Group and Women’s Voices for the Earth, see the US Modernization of Cosmetics Regulations Act of 2022 as a significant jump forward. But its “sweeping” preemption provisions could put consumers at risk, and its cosmetics safety substantiation standard is a step back from preexisting FDA regulations, the groups say.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel